pBabe puro HA PIK3CA E545K Citations (18)
Originally described in: The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells.Zhao JJ, Liu Z, Wang L, Shin E, Loda MF, Roberts TM Proc Natl Acad Sci U S A. 2005 Dec 20. 102(51):18443-8. PubMed Journal
Articles Citing pBabe puro HA PIK3CA E545K
| Articles |
|---|
| A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations. Kohsaka S, Shukla N, Ameur N, Ito T, Ng CK, Wang L, Lim D, Marchetti A, Viale A, Pirun M, Socci ND, Qin LX, Sciot R, Bridge J, Singer S, Meyers P, Wexler LH, Barr FG, Dogan S, Fletcher JA, Reis-Filho JS, Ladanyi M. Nat Genet. 2014 Jun;46(6):595-600. doi: 10.1038/ng.2969. Epub 2014 May 4. PubMed |
| Mutant PIK3CA controls DUSP1-dependent ERK 1/2 activity to confer response to AKT target therapy. Sathe A, Guerth F, Cronauer MV, Heck MM, Thalgott M, Gschwend JE, Retz M, Nawroth R. Br J Cancer. 2014 Nov 25;111(11):2103-13. doi: 10.1038/bjc.2014.534. Epub 2014 Nov 4. PubMed |
| Cellular context-mediated Akt dynamics regulates MAP kinase signaling thresholds during angiogenesis. Hellesoy M, Lorens JB. Mol Biol Cell. 2015 Jul 15;26(14):2698-711. doi: 10.1091/mbc.E14-09-1378. Epub 2015 May 28. PubMed |
| Transcriptional co-factor Transducin beta-like (TBL) 1 acts as a checkpoint in pancreatic cancer malignancy. Stoy C, Sundaram A, Rios Garcia M, Wang X, Seibert O, Zota A, Wendler S, Mannle D, Hinz U, Sticht C, Muciek M, Gretz N, Rose AJ, Greiner V, Hofmann TG, Bauer A, Hoheisel J, Berriel Diaz M, Gaida MM, Werner J, Schafmeier T, Strobel O, Herzig S. EMBO Mol Med. 2015 Jun 12;7(8):1048-62. doi: 10.15252/emmm.201404837. PubMed |
Activated mutant forms of PIK3CA cooperate with RasV12 or c-Met to induce liver tumor formation in mice via AKT2/mTORC1 cascade.
Wang C, Che L, Hu J, Zhang S, Jiang L, Latte G, Demartis MI, Tao J, Gui B, Pilo MG, Ribback S, Dombrowski F, Evert M, Calvisi DF, Chen X.
Liver Int. 2015 Dec 30. doi: 10.1111/liv.13055.
PubMed
Associated Plasmids |
| Multivalent Small-Molecule Pan-RAS Inhibitors. Welsch ME, Kaplan A, Chambers JM, Stokes ME, Bos PH, Zask A, Zhang Y, Sanchez-Martin M, Badgley MA, Huang CS, Tran TH, Akkiraju H, Brown LM, Nandakumar R, Cremers S, Yang WS, Tong L, Olive KP, Ferrando A, Stockwell BR. Cell. 2017 Feb 23;168(5):878-889.e29. doi: 10.1016/j.cell.2017.02.006. PubMed |
| PIK3CA hotspot mutations differentially impact responses to MET targeting in MET-driven and non-driven preclinical cancer models. Nisa L, Hafliger P, Poliakova M, Giger R, Francica P, Aebersold DM, Charles RP, Zimmer Y, Medova M. Mol Cancer. 2017 May 22;16(1):93. doi: 10.1186/s12943-017-0660-5. PubMed |
| A Preexisting Rare PIK3CA(E545K) Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in NRAS Melanoma and Is Dependent on S6K1 Signaling. Romano G, Chen PL, Song P, McQuade JL, Liang RJ, Liu M, Roh W, Duose DY, Carapeto FCL, Li J, Teh JLF, Aplin AE, Chen M, Zhang J, Lazar AJ, Davies MA, Futreal PA, Amaria RN, Zhang DY, Wargo JA, Kwong LN. Cancer Discov. 2018 May;8(5):556-567. doi: 10.1158/2159-8290.CD-17-0745. Epub 2018 Mar 1. PubMed |
| The Balance of PI3K and ERK Signaling Is Dysregulated in Prolactinoma and Modulated by Dopamine. Roof AK, Jirawatnotai S, Trudeau T, Kuzyk C, Wierman ME, Kiyokawa H, Gutierrez-Hartmann A. Endocrinology. 2018 Jun 1;159(6):2421-2434. doi: 10.1210/en.2017-03135. PubMed |
| The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. Razavi P, Chang MT, Xu G, Bandlamudi C, Ross DS, Vasan N, Cai Y, Bielski CM, Donoghue MTA, Jonsson P, Penson A, Shen R, Pareja F, Kundra R, Middha S, Cheng ML, Zehir A, Kandoth C, Patel R, Huberman K, Smyth LM, Jhaveri K, Modi S, Traina TA, Dang C, Zhang W, Weigelt B, Li BT, Ladanyi M, Hyman DM, Schultz N, Robson ME, Hudis C, Brogi E, Viale A, Norton L, Dickler MN, Berger MF, Iacobuzio-Donahue CA, Chandarlapaty S, Scaltriti M, Reis-Filho JS, Solit DB, Taylor BS, Baselga J. Cancer Cell. 2018 Sep 10;34(3):427-438.e6. doi: 10.1016/j.ccell.2018.08.008. PubMed |
| Regulation of glioma cell invasion by 3q26 gene products PIK3CA, SOX2 and OPA1. Schaefer T, Ramadoss A, Leu S, Tintignac L, Tostado C, Bink A, Schurch C, Muller J, Scharer J, Moffa G, Demougin P, Moes S, Stippich C, Falbo S, Neddersen H, Bucher H, Frank S, Jeno P, Lengerke C, Ritz MF, Mariani L, Boulay JL. Brain Pathol. 2018 Nov 7. doi: 10.1111/bpa.12670. PubMed |
| Nanomedicines blocking adaptive signals in cancer cells overcome tumor TKI resistance. Kinoh H, Shibasaki H, Liu X, Yamasoba T, Cabral H, Kataoka K. J Control Release. 2020 May 10;321:132-144. doi: 10.1016/j.jconrel.2020.02.008. Epub 2020 Feb 4. PubMed |
| Macropinocytosis confers resistance to therapies targeting cancer anabolism. Jayashankar V, Edinger AL. Nat Commun. 2020 Feb 28;11(1):1121. doi: 10.1038/s41467-020-14928-3. PubMed |
| USP28 enables oncogenic transformation of respiratory cells, and its inhibition potentiates molecular therapy targeting mutant EGFR, BRAF and PI3K. Prieto-Garcia C, Hartmann O, Reissland M, Braun F, Bozkurt S, Pahor N, Fuss C, Schirbel A, Schulein-Volk C, Buchberger A, Calzado Canale MA, Rosenfeldt M, Dikic I, Munch C, Diefenbacher ME. Mol Oncol. 2022 Sep;16(17):3082-3106. doi: 10.1002/1878-0261.13217. Epub 2022 Apr 30. PubMed |
| Activated TAZ induces liver cancer in collaboration with EGFR/HER2 signaling pathways. Moon H, Park H, Chae MJ, Choi HJ, Kim DY, Ro SW. BMC Cancer. 2022 Apr 19;22(1):423. doi: 10.1186/s12885-022-09516-1. PubMed |
| Trip13 Depletion in Liver Cancer Induces a Lipogenic Response Contributing to Plin2-Dependent Mitotic Cell Death. Rios Garcia M, Meissburger B, Chan J, de Guia RM, Mattijssen F, Roessler S, Birkenfeld AL, Raschzok N, Riols F, Tokarz J, Giroud M, Gil Lozano M, Hartleben G, Nawroth P, Haid M, Lopez M, Herzig S, Berriel Diaz M. Adv Sci (Weinh). 2022 Oct;9(29):e2104291. doi: 10.1002/advs.202104291. Epub 2022 Aug 28. PubMed |
| Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma. Wu Q, Ellis H, Siravegna G, Michel AG, Norden BL, Fece de la Cruz F, Balasooriya ER, Zhen Y, Silveira VS, Che J, Corcoran RB, Bardeesy N. Clin Cancer Res. 2024 Jan 5;30(1):198-208. doi: 10.1158/1078-0432.CCR-23-1317. PubMed |
| The SGK3-Catalase antioxidant signaling axis drives cervical cancer growth and therapy resistance. Wang M, Liu J, Liao X, Yi Y, Xue Y, Yang L, Cheng H, Liu P. Redox Biol. 2023 Nov;67:102931. doi: 10.1016/j.redox.2023.102931. Epub 2023 Oct 16. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.